The Effect Of Nimotuzumab Combined With TP Preoperative Induction Chemotherapy On IGFBP3 In Locally Advanced OSCC

Objective:To evaluate the efficacy of preoperative induction chemotherapy(PIC)with nimotuzumab combined with docetaxel and cisplatin for locally advance oral squamous cell carcinoma(LAOSCC).To determine the role of insulin-like growth factor binding protein 3(IGFBP3)in the process of nimotuzumab improving the chemosensitivity of LAOSCC to TP.Methods:The data of 27 patients with locally advanced oral cancer were collected from the Department of Oral and Maxillofacial Surgery of the First Hospital of Shanxi Medical University from August 2021 to December 2022.Among them,27 patients underwent preoperative induction chemotherapy and surgical treatment and were randomly divided into experimental group(nimotuzumab+docetaxel+cisplatin,N-TP)and control group(docetaxel+cisplatin,TP).The clinical efficacy of PIC was evaluated according to the evaluation criteria of clinical solid tumors.Collect samples from the diseased area,and detect the expression of IGFBP3 and EGFR in the two groups of patients by real time quantitative polymerase chain reaction(RT-PCR),Immunohistochemistry(IHC)and Western blot(WB).Results:According to the evaluation criteria of clinical solid tumor,the response rate(RR)of N-TP group(57.89%)was better than that of TP group(12.50%).RT-PCR results showed that the expression of EGFR was down-regulated and the expression of IGFBP3 was up-regulated in both groups,but compared with TP group,the down-regulation of EGFR and the up-regulation of IGFBP3 in N-TP group were more significant.Further,the IHC results and WB results showed the same trend,that is,the expression of EGFR in N-TP group was significantly decreased,and the expression of IGFBP3 was significantly increased.Conclusion:Nimotuzumab can effectively improve the chemosensitivity of LAOSCC patients to TP,and IGFBP3 may be one of the important molecules regulating this process.